Excel4apps announced that Cubist Pharmaceuticals, Inc., a Healthcare & Pharma organization based in MA, United States, have selected GL Wand to complement their Oracle Financial reporting toolset.About Cubist Pharmaceuticals
Cubist Pharmaceuticals, Inc. is a biopharmaceutical company focused on the research, development, and commercialization of pharmaceutical products that address unmet medical needs in the acute care environment.
Acute care is the space where we work and invest. In the U.S., Cubist markets CUBICIN® (daptomycin for injection), the first antibiotic in a class of anti-infectives called lipopeptides, and ENTEREG® (alvimopan), the first and only FDA-approved therapy to accelerate the time to upper and lower gastrointestinal recovery following partial large or small bowel resection surgery with primary anastomosis. Cubist also has an agreement with Optimer Pharmaceuticals, Inc. to co-promote Optimer's drug, DIFICID™ (fidaxomicin), in the U.S. as a treatment of Clostridium difficile-associated diarrhea (CDAD). Cubist's clinical product pipeline currently consists of a Phase 3 program focused on the development of a novel cephalosporin to address certain serious infections caused by multi-drug resistant (MDR) Gram-negative organisms, a Phase 3 program for the treatment of CDAD, and a Phase 3 program for the treatment of chronic opioid induced constipation (OIC). Cubist also is working on several pre-clinical programs being developed to address areas of significant medical needs. These include therapies to treat various serious bacterial infections and agents to treat acute pain.
Cubist is headquartered in Lexington, MA and employs approximately 700 people. 2013 Total net revenues grew 23% to $926.4 million compared to $754.0 million in 2012.
For more information on Cubist Pharmaceuticals, Inc. please visit www.cubist.com